Chiltern Announces Collaboration With Dr Nawab Qizilbash

LONDON, December 17 - Chiltern International Limited (Chiltern), a global clinical research
organization (CRO) providing clinical development and staffing services in
Europe, the Americas and Asia, is pleased to announce our collaboration with
Dr Nawab Qizilbash of OXON Epidemiology.

Dr Nawab Qizilbash, MBChB BSc MRCP (UK) MSc Phil (Oxon) is the Director
of OXON Epidemiology Ltd. He served as Director of Epidemiology and
Evidence-based Medicine at GlaxoSmithKline. Formerly an Honorary Consultant
Physician/Senior Research Fellow at Radcliffe Infirmary, Oxford University,
Nawab trained under Professor Sir Richard Peto F.R.S. in epidemiology, Phase
IV trials and meta-analysis. He also collaborates with Professor Stephen
Evans in academic research on statistical signal detection. Dr Qizilbash has
authored 5 publications in the Lancet, 1 in the Journal of the American
Medical Association and 1 in the British Medical Journal, among others. He
founded the Cochrane Dementia Group and is chief editor of an international
textbook on clinical dementia.

Jane Turner, MRPharmS, Chiltern's Late Phase Director, Europe, stated,
"We are delighted to announce the alliance between Chiltern Late Phase and Dr
Nawab Qizilbash and his company, OXON Epidemiology Ltd. OXON is a niche
consultancy company that specializes in 'real world data': epidemiology, risk
management and health economics. This partnership will allow Chiltern to
provide epidemiology and outcomes research expertise in conjunction with
flexible and bespoke late phase study solutions to our sponsors. Steve
Albrecht, Global head of Chiltern Late Phase, added, "We are excited about
this ongoing collaboration which significantly strengthens Chiltern's global
service offering in epidemiology, pharmacoeconomics and risk management.

Dr Qizilbash commented, "OXON is delighted to be collaborating with
Chiltern Late Phase. The combination provides scientific strength with
breadth and global reach to late phase, allowing for strategic consulting,
planning and implementation of: observational studies, risk management,
health economics and Phase IV trials."

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global clinical Contract
Research Organization with extensive experience conducting and staffing
international Phase I to Phase IV clinical trials across a broad range of
therapeutic areas for a wide variety of clients. Chiltern has conducted
trials in more than 40 countries and employs 1,400 people in 29 countries.
Chiltern provides Early Phase, Global Clinical Development, Late Phase,
Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services.
Further information: www.chiltern.com.

    For More Information:

    Natalie Chong, Chiltern International Ltd.
    171 Bath Road
    Slough, Berkshire SL1 4AA, UK
    Tel: +44-(0)1753-512-000
    Email: natalie.chong@chiltern.com

    Sue Ojanen, Chiltern International Inc.
    1241 Volunteer Parkway
    Bristol, TN 37620, USA
    Tel: +1-423-968-9533
    Email: sue.ojanen@chiltern.com

Natalie Chong of Chiltern International Ltd., +44-(0)-1753-512-000, natalie.chong at chiltern.com, or Sue Ojanen of Chiltern International Inc., +1-423-968-9533, sue.ojanen at chiltern.com